Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Radar On Market Access: Opioid Crisis

Posted by Matt Breese on Apr 19, 2018

While the fiscal year 2018 omnibus bill committed almost $4 billion to fighting the opioid epidemic, industry experts are debating who should be shouldering the blame for the crisis, AIS Health reported.
 
Meghan Oates-Zalesky, vice president of marketing at InCrowd, says, "though there was a concerted effort by a single drugmaker in the nineties to change prevailing attitudes towards opioids at the time, most manufacturers do not subscribe [to] such practices…[Yet,] it is never in the best interest for a manufacturer to ignore the harmful side effects of its drug."
 
Read More

Topics: Market Access, Provider, Payer

Radar On Market Access: New Financing Strategies for Innovative Therapies

Posted by Matt Breese on Apr 17, 2018

While breakthrough clinical treatments have the potential to change patients’ lives, their high upfront costs raise tricky questions for payers. A recent webinar hosted by the National Pharmaceutical Council explored some potential solutions to these financing challenges, AIS Health reported.
 
Finding a realistic and workable financing mechanism is important for patients, as the price tag for some new therapies is indeed steep. 
 
Read More

Topics: Specialty, Industry Trends, Market Access, Payer

MMIT Reality Check on Hepatitis C (Apr 2018)

Posted by Matt Breese on Apr 12, 2018

According to our recent payer coverage analysis for Hepatitis C treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

Radar On Market Access: Managing Specialty Drug Costs as Top Employer Concern

Posted by Matt Breese on Apr 12, 2018

As costs for specialty drugs continue to rise, managing those costs remains employers’ top concern, according to a recent Pharmacy Benefit Management Institute (PBMI) study.
 
Since 2011, medical benefit spending has risen 55%, and “double-digit average specialty trend under the pharmacy benefit has been the norm since 2007,” notes PBMI’s 2018 Trends in Specialty Drug Benefits
 
Read More

Topics: Industry Trends, Data & Analytics, Payer

Radar On Market Access: Value-Based Pricing

Posted by Matt Breese on Apr 10, 2018

With drug pricing on a continual upward path, many are looking to variations on the concept of value-based or outcomes-based pricing as a potential solution, according to AIS Health.
 
“While there has been a lot of attention on value-based contracts recently, the reality is that these are mostly pilot programs, and if you look closely at them, they are actually a fancy approach to traditional discounting,” says Peter Gilmore, a principal in the life sciences practice at KPMG. 
 
Read More

Topics: Industry Trends, Market Access

MMIT Reality Check on Detoxification Agents (Apr 2018)

Posted by Matt Breese on Apr 6, 2018

According to our recent payer coverage analysis for detoxification agents, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

Radar On Market Access: Immuno-Oncology Drugs

Posted by Matt Breese on Apr 5, 2018

As more oncology immunotherapies enter the U.S. market, manufacturers are working to effectively compete and gain market share, according to AIS Health.
 
Stephen Cichy at Monarch Specialty Group, LLC, points out that the definition of cancer is changing. The increased use of predictive biomarkers is leading to “an increase in the number of personalized medicines that can specifically target unique cancer populations.”
 
Read More

Topics: Industry Trends, Market Access, Product Release

Radar On Market Access: Senate Seeks to Bar "Gag Clauses"

Posted by Matt Breese on Apr 3, 2018

Two newly introduced Senate bills are aiming to bar health insurers and PBMs from using so-called “pharmacy gag clauses,” AIS Health reported.
 
On March 15, Sen. Susan Collins (R-Maine) and Sen. Claire McCaskill (D-Mo.) introduced the “Patient Right to Know Drug Prices Act” and the “Know the Lowest Price Act” that would prohibit an insurer or PBM from restricting a pharmacy’s ability to tell a patient when there is a difference between the cost of the drug under their insurance plan and the out-of-pocket cost of the drug. 
 
Read More

Topics: Industry Trends, Market Access, Payer

MMIT Reality Check on Antipsychotics (Mar 2018)

Posted by Matt Breese on Mar 29, 2018

According to our recent payer coverage analysis for atypical antipsychotic treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

Radar On Market Access: Pediatric and Adult Vaccines

Posted by Matt Breese on Mar 29, 2018

A concerted effort is underway to develop hepatitis A and B vaccines and vaccines against human papilloma virus (HPV) to prevent the incidence of certain types of cancers, according to AIS Health .
 
Though the return on investment for any given vaccine-related venture is anything but assured, vaccine franchises are becoming a viable source of revenue for many companies. The overall world vaccines market is predicted to grow from $34 billion in 2017 to $49 billion by 2022, according to an August 2017 study from market-research company MarketsandMarkets. 
 
Read More

Topics: Industry Trends, Market Access, Product Release